文献速递乳腺MR

欧洲乳腺影像学会关于乳腺扩散加权成像临床实践实施情况的调查

A survey by the European Society of Breast Imaging on the implementation of breast diffusion-weighted imaging in clinical practice.
PubMed 文献 · Eur Radiol · 2022-05-04

该调查向欧洲乳腺影像学会(EUSOBI)放射科医师会员发放在线问卷,共275/1411(19.5%)名会员回复,其中222/275(81%)将DWI纳入常规方案,主要用于病灶定性(ADC阈值1.2-1.3×10⁻³ mm²/s)和化疗反应预测;报告整合定性与定量DWI数据尚不统一。

要点

  • 多数回复者(81%)将乳腺DWI纳入常规方案,主要适应证为病灶定性和化疗反应预测。
  • 病灶定性常用ADC阈值为1.2-1.3×10⁻³ mm²/s,仅57%的回复者报告ADC值。
  • 报告整合不统一:76%提及扩散受限,但定量ADC值报告比例较低。

核心结论

  • 回复调查的EUSOBI放射科医师对乳腺DWI的临床应用总体符合国际推荐,主要应用于良恶性强化病灶鉴别、治疗反应评估和化疗反应预测,但报告对定性与定量DWI数据的整合尚不统一。

研究设计与样本

  • 由两名委员会认证放射科医师设计在线问卷,经EUSOBI董事会和委员会审核后发放给EUSOBI活跃及关联(非欧洲)放射科医师会员;问卷含20个问题,涵盖技术偏好、临床适应证、影像评估和报告;数据分析采用描述性统计、卡方独立性检验和Fisher精确检验。

诊断标准与关键数值

  • 病灶定性采用ADC阈值1.2-1.3×10⁻³ mm²/s;114/217(53%)回复者采集两个独立b值;在采集超过两个b值的回复者中,71/171(42%)首选b值=800 s/mm²进行评估;169/217(78%)不使用合成b值;161/213(76%)在MRI报告中提及扩散受限,142/217(57%)报告ADC值。

临床应用与阅片要点

  • 回复调查的EUSOBI放射科医师中,81%(222/275)将DWI纳入常规方案,常见适应证为病灶定性(ADC阈值1.2-1.3×10⁻³ mm²/s)和化疗反应预测;报告整合定性与定量DWI数据尚不统一。

局限性

  • 1411名EUSOBI放射科医师会员中仅275/1411(19.5%)回复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To perform a survey among all European Society of Breast Imaging (EUSOBI) radiologist members to gather representative data regarding the clinical use of breast DWI.

METHODS: An online questionnaire was developed by two board-certified radiologists, reviewed by the EUSOBI board and committees, and finally distributed among EUSOBI active and associated (not based in Europe) radiologist members. The questionnaire included 20 questions pertaining to technical preferences (acquisition time, magnet strength, breast coils, number of b values), clinical indications, imaging evaluation, and reporting. Data were analyzed using descriptive statistics, the Chi-square test of independence, and Fisher's exact test.

RESULTS: Of 1411 EUSOBI radiologist members, 275/1411 (19.5%) responded. Most (222/275, 81%) reported using DWI as part of their routine protocol. Common indications for DWI include lesion characterization (using an ADC threshold of 1.2-1.3 × 10-3 mm2/s) and prediction of response to chemotherapy. Members most commonly acquire two separate b values (114/217, 53%), with b value = 800 s/mm2 being the preferred value for appraisal among those acquiring more than two b values (71/171, 42%). Most did not use synthetic b values (169/217, 78%). While most mention hindered diffusion in the MRI report (161/213, 76%), only 142/217 (57%) report ADC values.

CONCLUSION: The utilization of DWI in clinical practice among EUSOBI radiologists who responded to the survey is generally in line with international recommendations, with the main application being the differentiation of benign and malignant enhancing lesions, treatment response assessment, and prediction of response to chemotherapy. Report integration of qualitative and quantitative DWI data is not uniform.

KEY POINTS: • Clinical performance of breast DWI is in good agreement with the current recommendations of the EUSOBI International Breast DWI working group. • Breast DWI applications in clinical practice include the differentiation of benign and malignant enhancing, treatment response assessment, and prediction of response to chemotherapy. • Report integration of DWI results is not uniform.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lo Gullo, Sevilimedu, Baltzer, et al. A survey by the European Society of Breast Imaging on the implementation of breast diffusion-weighted imaging in clinical practice. Eur Radiol. 2022. PMID: 35507050. doi:10.1007/s00330-022-08833-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。